Immunoprecise Stock Price, News & Analysis

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) announced a collaboration between its subsidiary Talem Therapeutics and Libera Bio to target intracellular mechanisms involved in cancer. The partnership will utilize BioStrand's LENSai® technology and Libera's Multifunctional Polymeric Nanocapsules (MPN Technology®) for developing novel therapies. The collaboration has stipulated a minimum of USD 155 million for milestone payments plus commercial royalties per product. This initiative aims to address high-unmet medical needs by targeting previously deemed 'undruggable' cancer targets, enhancing opportunities in oncology treatment.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host a quarterly earnings conference call on March 16, 2023, at 10:30 am Eastern Time. The discussion will cover Q3 fiscal year 2023 results and key business highlights. The earnings release will precede the call. Participants can join via toll-free and toll dial-in numbers, with a conference ID of 9236374. The call will be available for future playback on the company's investor relations page. Investors are encouraged to review the company's periodic reports with the Toronto Stock Exchange and the SEC for insights on financial performance and risk factors.

IPA (NASDAQ: IPA) reported a 9.8% increase in revenue for Q2 FY2023, totaling $5.2 million, driven by protein manufacturing and B cell Select® platform advancements. R&D expenses rose to $4.6 million due to costs associated with clinical manufacturing of the PolyTope® therapy. As of October 31, 2022, cash reserves were $15.1 million. Notably, IPA announced a collaboration with BriaCell Therapeutics to develop anti-cancer antibodies and confirmed the PolyTope TATX-03 neutralizing activity against the SARS-CoV-2 variant BA.2.75. However, the company voluntarily delisted from TSX Venture Exchange.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced that its subsidiary BioStrand BV has fully integrated 20 million Structural HYFTs with AI platforms AlphaFold-2 and ESM-2 Fold. This integration enhances the company’s protein structure prediction capabilities, creating a Knowledge Graph with over 660 million HYFTs and 25 billion relationships. This advancement supports faster drug discovery and efficiency in wet-lab experiments, marking a significant step in their biotherapeutic research and technology.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host an earnings conference call on Thursday, December 15, 2022, at 10:30 am Eastern Time to discuss its quarterly results and recent business highlights for Q2 fiscal year 2023. The company plans to release its financial results prior to the call. The management will take questions from participants following the presentation. Interested parties can join the call via provided phone numbers and a live webcast, which will also be available for replay on the company's investor relations page.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a collaboration with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW), focusing on AI-driven antibody discovery for cancer therapies. BioStrand, a subsidiary of IPA, will utilize its LENSai™ software to create clinical molecules. The partnership includes an upfront payment of US$500,000 for BioStrand, along with additional success-based milestones. This initiative aims to enhance the efficiency of developing targeted treatments, aligning with the long-term vision of advancing precision medicine.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced the voluntary delisting of its common shares from the TSX Venture Exchange (TSXV), effective November 25, 2022. The company cites low trading volume on the TSXV as a reason for this decision, believing that delisting will streamline operations and create a central marketplace on NASDAQ, enhancing long-term liquidity and shareholder value. Shareholders can continue trading IPA shares on NASDAQ, with many Canadian brokers providing access.

ImmunoPrecise Antibodies Ltd. (IPA) announced a strategic collaboration through its subsidiary, Talem Therapeutics, with OmniAb, Inc. This multi-target license agreement aims to develop three immuno-oncology programs targeting cancer markers B7H3, CD38, and TIM3. Talem will utilize its advanced laboratory and in silico technologies, including LENSai™, alongside OmniChicken antibody discovery technology. The partnership outlines shared downstream economics and positions Talem to accelerate the development of potential therapies leveraging AI-driven methodologies.

ImmunoPrecise Antibodies (IPA) has announced that its subsidiary, Talem Therapeutics, has received positive results from a study by the National Institute of Allergy and Infectious Diseases (NIAID). The study reaffirms the effectiveness of PolyTope® TATX-03 in neutralizing various SARS-CoV-2 variants, including new Omicron sublineages. IPA's Chief Scientific Officer highlighted the significance of this validation as they prepare for human clinical trials. This independent validation strengthens IPA's position in the market and showcases the product's potential against emerging COVID-19 variants.